1. Short title This Act may be cited as the Supporting Innovative Global Health Technologies Act of 2023 or the SIGHT Act . 2. Findings Congress finds the following: (1) The United States Agency for International Development has a unique role in the research and development of health technologies for global health that complements the work of other departments and agencies of the United States Government, having both an advantage and unique mandate for development of health technologies for use in low-resource settings. (2) It is in the national interest of the United States to build greater country capacity for research and development of new health technologies in low and middle-income countries. (3) Investments by the United States Government in global health research and development should be coordinated with and leverage investments from partner country governments, other government donors, and the private sector. (4) Human immunodeficiency virus, tuberculosis, malaria, neglected tropical diseases, emerging infectious diseases (such as COVID–19, Ebola, and Zika), and many other health conditions (such as complications in pregnancy) have a disproportionate public health burden in low- and middle-income countries. (5) Health technologies that were developed for use in high-income countries often cannot be implemented in low-resource settings in low- and middle-income countries or require adaptation to be effective. (6) Due to poverty or to low incidence, many neglected tropical diseases and emerging infectious diseases either lack or have limited commercial markets to drive health technology innovation. (7) Achieving the ambitious goals set through initiatives such as the President's Emergency Plan for AIDS Relief (commonly referred to as PEPFAR) and the President’s Malaria Initiative (commonly referred to as PMI ) will not be possible without the development and scale-up of new health technologies designed for use in low-resource settings, which are needed to address both long-standing endemic diseases and